news
Bile acids acting as inflammation regulators may protect against IBD
Research has found that bile acids, converted by gut microbes, act as inflammatory regulators in IBD by modulating the differentiation of T cells in the gut.
List view / Grid view
Inflammatory bowel disease (IBD)
article
DTR’s news round-up 2019: the stories that defined the year
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
news
New study could lead to better treatments for autoimmune diseases
A study has found a new molecular process in mice that causes autoimmune diseases and has opened avenues for developing more effective autoimmune therapies.
news
T cells could work as therapy for IBD in children, finds study
Researchers have found that a type of T cell, called a Tr1 cell, could work as a therapeutic strategy for inflammatory bowel disease in children.
news
Detecting epigenetic signature may help people stay ahead of IBD
Researchers have reported finding on an epigenetic signature in patient cells that appears to predict inflammation risk in Crohn's disease...
news
Gene manipulation holds the key to personalised medicine
Researchers propose a novel approach to manipulate genes that may hold the key to the future of personalised medicine...
news
Stem cell-derived intestine model mimics innate immune responses
A stem cell-derived in vitro model displays key small intestine characteristics including innate immune responses.
news
Researchers produce the first draft cell atlas of the small intestine
By surveying gene expression, researchers have created a reference atlas for understanding the biology of inflammatory bowel disease and food allergies, among other conditions...
news
CRISPR gives new insight into autoimmune disorders
Researchers have used a modified version of the gene-editing technique CRISPR in search for gene activators...
news
Mironid secures £4.3 million in Series A funding
20 June 2016 | By Victoria White, Digital Content Producer
The funding, led by Epidarex Capital, will support the Mironid’s internal research and preclinical development programmes...
news
Researchers identify interactions between immune system pathways
17 June 2016 | By Victoria White, Digital Content Producer
Researchers have identified interactions between immune system pathways which could improve the treatment of diseases such as inflammatory bowel disease...
news
Enterome signs IBD therapy agreement with Vertex
19 April 2016 | By Victoria White, Digital Content Producer
Enterome has signed a license agreement with Vertex to research, develop and commercialise novel small molecule FimH antagonists...
news
Galapagos licenses HUB Organoid Technology for use in cystic fibrosis and IBD research
15 July 2015 | By Victoria White
Galapagos has entered into a licensing agreement with the HUB foundation for use of Organoid Technology for preclinical research in cystic fibrosis and IBD...
